<DOC>
	<DOCNO>NCT00869973</DOCNO>
	<brief_summary>The aim study compare efficacy tolerability aprepitant versus dexamethasone prevention delay emesis induce moderately emetogenic chemotherapy ( cyclophosphamide plus anthracyclines ) breast cancer patient .</brief_summary>
	<brief_title>Aprepitant Prevention Delayed Emesis Induced Cyclophosphamide Plus Anthracyclines Breast Cancer Patients</brief_title>
	<detailed_description>This phase III , double-blind , randomize trial , evaluate efficacy safety aprepitant prevention delay emesis patient breast cancer submit first time chemotherapy cyclophosphamide plus anthracyclines . The study carry first cycle chemotherapy . For prevention acute emesis , patient receive , chemotherapy : - dexamethasone 8 mg iv 15 minute , 30 minute chemotherapy ; - palonosetron 0.25 mg iv bolus , 30 minute chemotherapy - aprepitant 125 mg orally , 60 minute chemotherapy After 24 hour chemotherapy administration , patient randomize receive : A ) dexamethasone 4 mg orally : 24 hour chemotherapy 8 pm day 2 , 8 8 pm day 3 . B ) Aprepitant 80 mg orally : 24 hour chemotherapy day 2 8 day 3 . The patient receive prochlorperazine suppository rescue medication , important nausea vomiting ( &gt; 2 episode ) day 1-5 chemotherapy . The patient receive diary , include Visual Analogue Scale ( VAS ) nausea vomit evaluation . All patient fill diary , 6 consecutive day ( day 1-6 ) , patient report day number vomit episode , intensity duration nausea , antiemetic rescue medication adverse event treatment . In addition , day 1 chemotherapy day 6 , patient fill FLIE ( Functional Living Index-Emesis ) , questionnaire concern impact nausea vomit quality life . Primary end point percentage complete response ( vomit rescue treatment ) day 2-5 chemotherapy administration</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>patient breast cancer , receive first time chemotherapy cyclophosphamide + anthracyclines ( FAC , FEC , AC , EC ) . patient 18 year old sign informed consent adequate contraception premenopausal woman Every anticancer drug first 24 hour administered end cyclophosphamide plus anthracycline . patient already submit chemotherapy patient receive chemotherapy day 24 treatment patient concomitant severe disease predisposition emesis intestinal obstruction , active peptic ulcer , hypercalcemia brain metastasis contraindication corticosteroid ( i.e. , active peptic ulcer previous bleed peptic ulcer patient submit concomitant radiotherapy submit radiotherapy 15 day chemotherapy plan receive radiotherapy 8 day chemotherapy patient receive concomitant antiemetic treatment submit antiemetic treatment 24 hour chemotherapy patient nausea vomit 24 hour chemotherapy patient receive concomitant steroid , except administer physiologic dos patient receive concomitant benzodiazepine , except use nocturnal sedation patient WBC count &lt; 3000/mm3 platelet count &lt; 70000/mm3 patient pregnant breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>aprepitant</keyword>
	<keyword>delay emesis</keyword>
	<keyword>cyclophosphamide plus anthracyclines</keyword>
	<keyword>breast cancer</keyword>
	<keyword>antiemetic</keyword>
</DOC>